ESTRO 2022 - Abstract Book

S629

Abstract book

ESTRO 2022

Results Between 2010 and 2020, 119 CIED pts were treated in our Radiation Oncology Department. We report the data related to 75 pts (63.0%), where the CIED was included in the CT-Scan and identified as OAR. 60 pts (80%) had thorax radiotherapy, while for 15 pts (20%) RT was extra thoracic. Twenty-three (30%) pts were at high risk. Median Dmax and Maximum Doses delivered to CIED and lead were 1.23 Gy- 20.0 Gy and 17.23 Gy- 64.16 Gy respectively. 45 CIEDs (60%) received £2 Gy, 26 CIEDs (34.7%) a Dmax between 2 and 10 Gy, and 4 CIED (5.3%) received a Dmax> 10 Gy. 34 Leads (45.3%) received > 10 Gy. During CIED interrogations, no hardware failure was detected, neither in CIED, nor in Lead. Conclusion In our experience, CIED pts can undergo safely to radiation treatment. Even for high-risk pts, especially where Dmax at CIED was > 2 Gy no CIEDs failures were observed. To the best of our knowledge, this study is the first that included CIED and lead as distinct OAR, in order to evaluate their dose distribution. Even if Dmax of lead was high, the effect was not clinically significant.

MO-0718 An inpatient radiation oncology consult service is associated with shorter hospital length of stay

M. Freret 1 , D. Yerramilli 1 , O. Cahlon 1 , S. Powell 1 , J. Yang 1 , S. McBride 1 , D. Gomez 1 , A. Xu 1

1 Memorial Sloan Kettering Cancer Center, Radiation Oncology, New York, USA

Purpose or Objective Radiation therapy has an expanding role in the management of patients with advanced cancers, including in the palliative and oligometastatic settings. We previously described an inpatient radiation oncology consult (IROC) service created to deliver rapid, specialized metastatic cancer care to hospitalized patients. Here we report an 18-month update on IROC patient outcomes to test the hypothesis that IROC decreased hospital length of stay (LOS) and led to more prognosis- appropriate care, including during the first peak of the COVID-19 pandemic. Materials and Methods The IROC service started in January 2020 and comprises faculty, advanced practice providers, nurses and resident trainees. Faculty are specialists in palliative and metastatic cancer care with certification in ablative radiation techniques. We compared inpatient radiation oncology consults placed from January to December 2019 (pre-IROC, N = 1,507) to those placed from June 2020 to June 2021 (IROC, N = 1,509). In a separate analysis, we examined consults during a non- overlapping period from March to June 2020 ( N = 302) to assess changes in IROC practice patterns related to the peak of the COVID-19 pandemic in New York City. Statistical significance was assessed using the Mann-Whitney test. Results Hospital LOS decreased among all inpatient radiation oncology consult patients after implementation of IROC ( N = 1,509 patients) by an average of 1.0 day compared to patients treated prior to IROC ( N = 1,507 patients; P = 0.045). With IROC, consults were staffed an average of 0.6 days sooner ( P < 0.001). Death within 60 days of inpatient RT decreased under IROC (35.4%, N = 187/528 patients) compared to prior (43.7%, N =241/551 patients, P = 0.005). Among patients discharged to hospice, inpatient treatment duration decreased after IROC (median 4 vs. 2 days, pre-IROC ( N = 64 patients) vs. IROC ( N = 82 patients), respectively, P = 0.033). The IROC service received consults for 21 patients infected with SARS-CoV-2, and 17 patients had active COVID-19 during treatment. Notably, hospital LOS for patients receiving inpatient RT under IROC was significantly shorter during the COVID-19 peak (median LOS 9 days, P < 0.001), when time to treatment decreased by an average of 2.5 days ( P = 0.004) and treatment length decreased by 1.9 days ( P < 0.001) compared to the pre-IROC period.

Conclusion A dedicated inpatient radiation oncology consult (IROC) service was associated reduced hospital LOS, faster care delivery, and more prognosis-appropriate care. It enabled rapid implementation of emergency RT guidelines, including abbreviated treatment durations, during the first COVID-19 peak in a pandemic hotspot.